These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The use of systemic and topical fluoroquinolones. Bradley JS; Jackson MA; ; Pediatrics; 2011 Oct; 128(4):e1034-45. PubMed ID: 21949152 [TBL] [Abstract][Full Text] [Related]
5. [Clinical position of sitafloxacin in outpatient chemotherapy. (discussion)]. Niki Y; Aoki N; Suzuki K; Matsumoto T Jpn J Antibiot; 2009 Jun; 62(3):179-93. PubMed ID: 19882979 [No Abstract] [Full Text] [Related]
6. [Which partner for the betalactam agent in empiric combined therapy? I Fluoroquinolone]. Bedos JP Ann Fr Anesth Reanim; 2004 Jun; 23(6):636-8. PubMed ID: 15234734 [No Abstract] [Full Text] [Related]
7. Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. de Lastours V; Fantin B Future Microbiol; 2015; 10(7):1241-55. PubMed ID: 26119580 [TBL] [Abstract][Full Text] [Related]
8. Clinical studies of garenoxacin. Takagi H; Tanaka K; Tsuda H; Kobayashi H Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608 [TBL] [Abstract][Full Text] [Related]
10. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. Blondeau JM; Tillotson G Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120 [TBL] [Abstract][Full Text] [Related]
11. [Osteoarticular infections: therapeutic proposals of the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP)]. Grimprel E; Lorrot M; Haas H; Pinquier D; Parez N; Ferroni A; Cohen R; Arch Pediatr; 2008 Oct; 15 Suppl 2():S74-80. PubMed ID: 19000859 [TBL] [Abstract][Full Text] [Related]
12. FDA and the safe and appropriate antibiotic use of fluoroquinolones. Tillotson GS Lancet Infect Dis; 2016 Mar; 16(3):e11-2. PubMed ID: 26973315 [No Abstract] [Full Text] [Related]
13. IAP Task Force Report: management of enteric fever in children. Kundu R; Ganguly N; Ghosh TK; Yewale VN; Shah RC; Shah NK; Indian Pediatr; 2006 Oct; 43(10):884-7. PubMed ID: 17079831 [No Abstract] [Full Text] [Related]
14. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. Gagliotti C; Buttazzi R; Sforza S; Moro ML; J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763 [TBL] [Abstract][Full Text] [Related]
16. What's new on the antimicrobial horizon? Song JH Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521 [TBL] [Abstract][Full Text] [Related]
17. Coping with antibiotic resistance: the impending crisis. Gould IM Int J Antimicrob Agents; 2010 Nov; 36 Suppl 3():S1-2. PubMed ID: 21129626 [TBL] [Abstract][Full Text] [Related]
18. The use of systemic fluoroquinolones. Committee on Infectious Diseases Pediatrics; 2006 Sep; 118(3):1287-92. PubMed ID: 16951028 [TBL] [Abstract][Full Text] [Related]
19. Appropriate use of fluoroquinolones in children. Principi N; Esposito S Int J Antimicrob Agents; 2015 Apr; 45(4):341-6. PubMed ID: 25726705 [TBL] [Abstract][Full Text] [Related]